News and Announcements
Shivom’s Presale is now Live! Sign up now & Complete KYC for Crowdsale
- Published April 16, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Today, April 16th, 2018 marks the launch of Shivom’s presale and an essential step in our journey. We are so thrilled and invite all of you (in case you still have not) to sign up for the public presale event! The public presale will continue until April 22nd, 2018, so don’t miss your chance to register and complete KYC early!
The Shivom OmiX presale event can be found at: https://tokensale.
Why sign up for the Shivom Presale?
We are offering an early bird advantage to everyone who has signed up for the Presale:
-
Sale of the first 15 000 ETH worth of tokens at 10% discount on 16th April. This bonus will decrease by 1% each day.
-
Last chance to buy OmiX tokens at 1 ETH = 7000 OmiX
Registration is free, simple, and fully secured. Every user will have to complete KYC before being eligible for the purchase of OmiX tokens.
If you have already registered for the presale through our platform, make sure your KYC is completed. KYC is not required to purchase tokens, but it is required to obtain your purchased tokens during token distribution.
So grab this opportunity while you still can and join the Shivom community to help transform the future of global healthcare and precision magazine.
Register here.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
